Bio Green Med Solution, Inc. quarterly report, Q3 FY2023

Business context and reporting period

The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2023, filed November 28, 2023. This does not match the request metadata naming Bio Green Med Solution, Inc.; verify the issuer before relying on this summary.

Cyclacel is a clinical-stage biopharmaceutical company developing cancer therapies. Its programs include fadraciclib, a CDK2/9 inhibitor, and plogosertib, a PLK1 inhibitor. The filing reports 26 evaluable patients treated in the fadraciclib Phase 1/2 study and 14 in the plogosertib study; no dose-limiting toxicities had been observed in the latter at the reported dose-escalation levels.

Key financial metrics

Amounts below are in U.S. dollars; financial statement amounts are unaudited and generally presented in thousands.

For the nine months, operating cash outflow was $12.202 million, investing outflow $6,000, and financing outflow $151,000. Cash declined by $12.401 million from the start of the year. Cash receipts included $4.846 million in U.K. R&D tax credits. The filing does not report conventional profit margins meaningful for this loss-making, clinical-stage business.

Material changes versus comparable periods

• Nine-month R&D expense rose 15% to $15.637 million. Fadraciclib-related expense increased $1.943 million, while plogosertib expense was broadly flat.
• Nine-month general and administrative expense fell 8% to $4.845 million, primarily because the prior-year period included a non-recurring $0.4 million Sales Agreement cost.
• Other income declined to $235,000 from $1.896 million in the first nine months of 2022. The prior-year figure included approximately $1.3 million of royalty-related income; foreign exchange also shifted from a gain to a small loss.
• Despite a larger net loss, operating cash use improved by $3.456 million year over year, mainly from working-capital changes, including tax-credit receipts and clinical-trial deposits.
• Common shares outstanding increased to 12,642,822 from 9,422,089 at December 31, 2022, largely reflecting reclassification of shares previously treated as redeemable or temporary equity. As of September 30, no claims or demands to exercise the related rescission rights had been reported.

Outlook, risks, contingencies and unusual items

• Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months after issuance. Cash at September 30 was expected to fund operations through year-end 2023. Discretionary spending reductions and an anticipated approximately $3.1 million R&D tax-credit receipt in Q1 2024 could extend liquidity into Q2 2024, but neither additional financing nor partnership funding is assured.
• Funding dependence: The company expects continued operating losses and says it lacks sufficient funds to complete development and commercialization of its candidates. It may seek equity or debt financing or partnerships; failure to obtain funding could delay, reduce, or eliminate trials or programs.
• Operating outlook: Management expected 2023 R&D and G&A spending to be lower than in 2022, citing a temporary halt to the Phase 1/2 hematological-malignancy study and efforts to reduce professional costs. The filing provides no revenue or earnings guidance.
• Restatement and control weakness: The company disclosed prior-period accounting errors involving contract deposits and equity transactions. Contract-related invoices totaling about $549,000 had been expensed rather than recorded as non-current deposits, and associated R&D tax credits were misstated. The filing also describes errors in accounting for shares with potential rescission rights and related fees. Management said the corrections did not change reported 2023 or 2022 net loss for the comparative periods.
• Internal controls: Management concluded disclosure controls were not effective at the reasonable-assurance level because of material weaknesses in controls over contractually required deposits and complex, non-routine equity transactions. Remediation was ongoing and not considered complete; the company gave no assurance it would be successful.
• Tax-credit uncertainty: U.K. R&D tax-credit benefits declined year over year following legislative changes effective April 2023. Future eligibility and amounts are uncertain, including possible HMRC eligibility changes or caps.
• Other: No legal proceedings or material risk-factor changes were reported in this filing. A $0.15-per-share quarterly dividend on the 6% preferred stock was declared September 6 and paid November 1, 2023.

Important facts for investors to verify

• Confirm issuer identity: the supplied text is a Cyclacel Pharmaceuticals filing, not a Bio Green Med Solution filing.
• Check subsequent cash, financing, partnership, and tax-credit developments against the stated short runway and going-concern uncertainty.
• Review progress and costs of the fadraciclib and plogosertib trials, including the planned pause in hematological-malignancy work.
• Assess the restatement disclosures, the share reclassification and rescission history, and whether the identified control weaknesses have been remediated.
• Verify current share count, preferred-stock obligations, potential dilution from options and warrants, and any later changes to the dividend or capital structure.